This article was originally published in Start Up
It's rare to find a drug development start-up that has grown to more than 50 people and raised over $100 million before putting its first molecule into the clinic. That's the history of CovX, which uses a humanized antibody as a scaffold for developing multiple drugs with the desirable properties of both the antibody and specific peptides or small molecules that are linked to it.
You may also be interested in...
A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.